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Tumor necrosis factor (TNF) and interleukin 1 (IL-l) are both cytokines of macrophage origin with similar activity on 
several cell types. We investigated whether TNF can, analogously to IL-l, stimulate phospholipase activity of chondro- 
cytes. Addition of each of these cytokines to cells, isolated from the xiphistemum of adult rats, resulted in a time- and 
dose-dependent increase in phospholipase activity in both secreted and membrane-associated form. Moreover, TNF and 
IL-1 both induce a transformation of chondrocyte morphology. In conclusion, TNF stimulates chondrocyte phospho- 
lipase activity and extends the long list of actions shared by IL-l and TNF in a diversity of cellular systems. 
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1. INTRODUCTION 
Inflammation of joints is associated with 
degradation of connective tissue; this is believed to 
be mediated by macrophage-derived polypeptides, 
such as IL-l, produced after stimulation. This 
monokine exerts a wide range of biological ac- 
tivities, some of which lead to bone resorption and 
cartilage destruction [1,2]. These activities are at 
least partly mediated by an IL- 1 -induced activation 
of PLA2 resulting in production of PGEz in 
cultured chondrocytes [2] and bones [3]. Two 
distinct human IL-l-cDNAs have been cloned and 
expressed [4]. The corresponding monokines, 
IL-la and IL-l@, both bind to the same receptor, 
apparently without strict species preference [5]. 
Tumor necrosis factor is another macrophage- 
and monocyte-derived protein that has been 
described to exert multiple effects on different 
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biological systems [6]. Its most promising action is 
a specific cytotoxic activity towards certain tumor 
cells, both in vivo and in vitro [7]. TNF cDNA has 
been cloned by several groups; its expression in 
Escherichia colt’ results in biologically active, 
recombinant TNF [8-lo]. Fiers et al. [ 1 l] reviewed 
the many activities shared by TNF and IL-l, in- 
cluding some possibly involved in inflammation 
and tissue damage. TNF, analogous to IL-l, 
stimulates collagenase and PGEz production by 
synovial cells and fibroblasts [ 121. Furthermore, 
both TNF and IL-l stimulate phospholipid 
hydrolysis in synovial cells [ 131. 
These data led us to investigate whether TNF 
can activate phospholipase activity in chon- 
drocytes. 
2. MATERIALS AND METHODS 
2.1. Isolation and cultivation of chrondrocytes 
Chondrocytes were released by enzymatic digestion of 
xiphisternum slices of adult Fischer rats by a procedure slightly 
modified after Benya et al. [14]. Cells were grown in Dulbecco’s 
modified minimal essential medium (DMEM, Gibco Europe, 
Ghent, Belgium), supplemented with 5% heat-inactivated (30 
min at 56°C) newborn calf serum (Gibco Europe), 100 U/ml 
penicillin and 0.1 mg/ml streptomycin. 
24 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 0 1988 Federation f European Biochemical Societies 
Volume 232, number 1 FEBS LETTERS May.1988 
2.2. Phospholipase xtraction Table 1 
Cells grown in 10 cm* Petri dishes to confluency were rinsed 
twice with DMEM and incubated in the presence of TNF or 
IL-l in 1 ml serum-free medium. At appropriate times superna- 
tant was extracted as .follows. Cells were rinsed twice with ice- 
cold buffer (10 mM Hepes+0.5 mM MgCl2, pH 7.5) and 
scraped off with a rubber policeman in 300 ~1 of the same ice- 
cold buffer. After 30 min incubation on ice the cell suspension 
was dounced 30 times; the membranes were isolated by cen- 
trifuging at 2000 x g for 5 min, followed by a second centrifuga- 
tion of the supernatant at 10000 xg for 10 min. Phospholipase 
was then differentially extracted in 0.18 N HzS04. 
Dose-dependent increase in phospholipase activity in the 
supernatant of rat condrocytes in the presence of increasing 
concentrations of IL-l or TNF for 72 h 
2.3. Assay for phospholipase activity 
Phospholipase activity was measured by the hydrolysis of 
[‘4C]arachidonic acid;labeled E. coli phospholipids [IS]. 50 ~1 
of phospholipase xtract and 2.5 x 10’ labeled E. coli bacteria 
(10000 cpm) were adjusted to a total volume of 0.5 ml with 100 
mM Tris, pH 7.5, and 5 mM CaClz buffer. Incubation took 
place for 15 min at 37°C. The reaction was stopped by addition 
of 1.5 ml of chloroform/methanol (1:2; v/v), followed by 
vigorous shaking for 15 min at 37°C. Finally, 1 ml of 
chloroform and 1.5 ml of water were added and mixed; the 
lower chloroform/lipid phase was removed and evaporated. 
The dry residue was redissolved in 50 ~1 of chloroform/ 
methanol (9: 1, v/v) and spotted on silica gel thin-layer 
chromatography plates (Merck, Darmstadt, FRG). These were 
developed in a solvent system containing petroleum 
ether : diethyl ether : acetic acid (80 : 20 : 1, v/v). Radioactive 
spots were localized by fluorography according to Bonner et al. 
[16] and cut from the plate for liquid scintillation counting. The 
percentage of hydrolysis was calculated as follows (all values in 
cpm): 
U/ml of monokine Phospholipase activity (070 hydrolysis) 
used after treatment with 
TNF IL-l 
0 7.0 7.0 
1 7.9 9.8 
3 7.3 11.4 
10 9.1 12.8 
33 11.2 12.0 
100 16.0 15.0 
330 15.0 15.9 
1000 18.1 16.9 
3300 21.4 17.8 
1). Furthermore, the increase in enzyme activity 
was caused by stimulation of neither chondrocyte 
proliferation nor non-specific secretion of protein, 
as there was no difference in the amount of ex- 
tracellular protein between cells treated or un- 
treated with TNF or IL-l. 
In spite of some background activation in the 
untreated control, it was clear that secreted 
phospholipase activity also increased according to 
the duration of TNF or IL-l treatment (fig.1). In 
agreement with the results obtained by Chang et al. 
[2] we found that the increase in monokine- 
mediated phospholipase release requires a relative- 
ly long period of TNF or IL-l treatment. 
free fatty acid 
x 100. 
total phospholipid + free fatty acid 
The values were corrected for spontaneous release of 
[‘4C]arachidonic acid from E. coli (ranging from 3.8 to 6%). 
2.4. Monokine preparations 
Recombinant human TNF was produced by E. co/i and 
purified to at least 99% homogeneity [lo]. ,The preparation 
used had a specific activity of 2 to 3 x 10’ Wmg protein (units 
as defined by Ostrove and Gifford [17] in a cytotoxicity assay 
on L929 cells). The preparation contained less than 13 ng/mg 
endotoxin; it was stored in aliquots in phosphate-buffered 
saline at - 7O’C. Recombinant human IL-lfi was a gift from Dr 
A. Shaw (Biogen SA, Geneva, Switzerland); the specific activity 
was 2.7 x IO* U/mg protein (units as defined by Erard et al. [18] 
in a cytotoxicity-induction assay with PC60 cells). 
3. RESULTS AND DISCUSSION 
Treatment of chondrocytes in culture in serum- 
free medium with TNF or IL-l resulted in an in- 
crease in extracellular phospholipase activity. This 
increase was dose dependent and still increasing in 
the range of monokine concentrations tested (table 
As it is known that PLAz is a membrane-bound 
enzyme [19], we investigated the effect of TNF on 
cell-associated phospholipase activity. Treatment 
of chondrocytes for 48 h with various concentra- 
tions of TNF or IL-l resulted in a dose-dependent 
stimulation of membrane-associated phospholi- 
pase activity (fig.2). In these (and previous) ex- 
periments we did not determine the specificity of 
the phospholipase involved. It is, however, likely 
that the enzyme is PLAz, because (i) most 
arachidonic acid added to E. coli is incorporated in 
the CZ position of phospholipids [2]; (ii) IL-l in- 
duces PLA2 [2]; (iii) we previously found evidence 
for an involvement of PLA2 in TNF-action in 
mouse fibrosarcoma cells [20]. 
Cultured chondrocytes have a typically flat mor- 
phology. After treatment with TNF, and especially 
with IL-I, the cells acquire a more contracted and 
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Fig. 1. Effect of the addition of 5000 U TNF/ml or 5000 U IL-l /ml on phospholipase activity in the supernatant of rat chondrocytes 
as a function of time. 
refractile morphotype (fig.3). We do not know if 
there is a correlation between the increased 
phospholipase activity and this change in mor- 
phology. It was, however, found that the effect of 
IL-l on cell morphology is much more pronounced 
than that of TNF, at a concentration at which both 
monokines stimulate phospholipase activity equal- 
01 
0 10 100 1000 10000 
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Fig.2. Dose-related induction of membrane-bound phospho- 
lipase activity of rat chondrocytes after treatment with 
increasing concentrations of TNF or IL-l. The cultures were 
treated for 48 h with TNF (A) or IL-1 (T). 
ly well. TNF induces phospholipase activity in 
mouse fibrosarcoma cells [20-221; this seems, 
however, not to be the only mechanism that 
regulates the sensitivity of a given cell line towards 
TNF or IL-l-induced cytotoxicity. Indeed, chon- 
drocytes - which also show an increased 
phospholipase activity after treatment with these 
monokines - are not sensitive to the cytotoxic ac- 
tion of TNF or IL-l. 
The mechanism by which TNF and IL-l activate 
phospholipase still needs to be determined. Possi- 
ble explanations are: modulation of lipocortin ac- 
tivity, modulation of phospholipase activity 
protein, regulation of Ca’+ inflow, proteolytic ac- 
tivation of phospholipase, induction of membrane 
changes or de novo synthesis (review [19]). We do 
not yet know whether both TNF and IL-l activate 
phospholipase through the same mechanism. Both 
could, however, be important mediators of some 
diseases such as rheumatoid arthritis [23], con- 
sidering that soluble phospholipase has been 
detected in rheumatoid synovial fluid [24]. 
Phospholipase induction in -chondrocytes, as 
reported here, is one more example of the 
biological activities shared by TNF and IL-l. Con- 
sequently, it is the more striking that these two 
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Fig.3. Morphotype of rat chondrocytes influenced by treatment with TNF or IL-l. A confluent monolayer of chondrocytes was either 
untreated (A), or stimulated with 5000 U/ml IL-l (B) or 5000 U/ml TNF (C) for 72 h. Phase contrast micrographs using a 25 x 
objective. 
monokines exert, generally speaking, dissimilar 
cytotoxicity-inducing activities on malignant cells 
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